]>
IRCT2015060222541N1 IRCT 2016-06-24 Vice Chancellor of Research, Shiraz University of Medical Sciences Comparing hormone profile and outcomes of ovulation triggering with GnRH and HGC in IVF A prospective randomized clinical trial on mid-cycle triggering of final oocyte maturation using GnRH versus HCG in Antagonist protocol 2013-02-26 anticipated 232 Complete https://irct.ir/trial/19427 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Randomisation will be implemented using table of random numbers. 2-3 Female infertility. Intervention 1: Intervention group: In intervention group the patient will receive GnRh agonist (Decapeptyl; Ferring, The Netherlands), 0.2 mg sc for triggering final oocyte maturation. Intervention 2: Control group: In control group the patients will receive HCG 10000 IU sc (Institute Biochimique SA (IBSA), The Switzerland) for triggering final oocyte maturation.
public Dr. leila Sarikhani
OB. & GYN. Office, Shahid Faghihi Hospital, Zand Street
Shiraz Iran (Islamic Republic of) +98 71 3229 8396 sarikhani_l@sums.ac.ir; dr.l.sarikhani@gmail.com OB. & GYN Department, Shiraz Medical School scientific Dr. Ebrahim Parsanezhad
OB. & GYN. Department, Shahid Faghihi Hospital, Zand Street
Shiraz Iran (Islamic Republic of) +98 71 3233 2365 parsame@rogers.ca; obgynward@sums.ac.ir OB. & GYN. Department, Shiraz Medical School Iran (Islamic Republic of) Inclusion criteria: All patients who are candidate for IVF/ICSI( Male factor infertility, unexplained infertility, tubal factor infertility), Age below 39 years old, BMI: 18-29, Regular menstrual cycles.Agreement of patient to enrol the research Exclusion criteria: Ovulatory factor infertility, Endometriosis, Uterine anomalies, Age above 39 years old, Non-agreement of patient to enrol the research 24 years 36 years Female N97.9 Female infertility Treatment - Drugs Treatment - Drugs Intervention group: In intervention group the patient will receive GnRh agonist (Decapeptyl; Ferring, The Netherlands), 0.2 mg sc for triggering final oocyte maturation Control group: In control group the patients will receive HCG 10000 IU sc (Institute Biochimique SA (IBSA), The Switzerland) for triggering final oocyte maturation Number and Quality of oocytes retrieved in each IVF cycle. Timepoint: on day of ovum pick up. Method of measurement: measuring number and quality of oocytes on the day of pick up by pathologist in lab under microscope and scoring. Progesterone level. Timepoint: on the day of injection HCG or GnRH agonist(Final Triggering) and rechecked 7 and 14 days after that. Method of measurement: Serum Level, Lab test. Number and Quality of embryos transferred in IVF cycle. Timepoint: on day of embryo transfer. Method of measurement: measuring number and quality of embryos by pathologist in lab under microscope and grading. Comparing FSH, LH, Estradiol and HCG in both groups. Timepoint: on days 2 and 6 of menstrual cycle, final oocyte triggering, oocyte retrieval, 7 and 14 days after that oocyte retrieved. Method of measurement: Serum Level, Lab test. Rate of ovarian hyperstimulation syndrome (OHSS). Timepoint: From day of HCG or GnRH agonist injection up to 2 weeks later. Method of measurement: Clinical management of symptoms, Sonography. Clinical Pregnancy. Timepoint: 16 days after triggering if menstruation was absent. Method of measurement: Serum BHCG and TVS. 90-01-01-3979 Shiraz University of Medical Sciences Vice Chancellor of Research, Shiraz University of Medical Sciences Approved 2013-02-21 Ethics Committee of Shiraz University of Medical Science Shiraz University of Medical Science , Zand street Shiraz Iran (Islamic Republic of)